Oxford University Innovations Ltd. has synthesized hypoxia-activated proteolysis targeting chimeras (hypoxia-activated PROTACs; HAP-TAC) comprising a hypoxia-activated moiety modified E3 ubiquitin ligase-binding moiety coupled to a protein targeting moiety through a linker reported to be useful for the treatment of cancer.

Shanghai Yidi Biotechnology Co. Ltd. has disclosed neutrophil elastase (ELANE; leukocyte elastase) inhibitors reported to be useful for the treatment of pain and respiratory tract inflammation.

Abbisko Therapeutics Co. Ltd. has divulged CDK4/cyclin D3 inhibitors reported to be useful for the treatment of cancer.

Oxford University Innovation Ltd. has reported radiolabeled compounds reported to be useful for the diagnosis and treatment of cancer. An unlabeled form of an exemplified compound ([68Ga]-KK02 pg 33) inhibited PARP1 activity (IC50=9.1 nM).

A Suven Life Sciences Ltd. patent has detailed new N-aryl benzamide derivatives acting as P2X purinoceptor 7 (P2RX7; P2X7) antagonists. As such, they are believed to be potentially useful for the treatment of cancer, pain, renal, neurological, endocrine and psychiatric disorders.

Work at Vir Biotechnology Inc. has led to the identification of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).

Aurigene Oncology Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising a protein cereblon (CRBN)-binding moiety covalently bound to a CREB-binding protein (CREBBP; CBP)-targeting moiety through a linker.

Several recent Atavistik Bio Inc. patents describe substituted aminopyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors, particularly AKT1 (E17K mutant) reported to be useful for the treatment of cancer.

NLRP3 inflammasome inhibitors are described in a Zomagen Biosciences Ltd. patent and are reported to be useful for the treatment of autoimmune, cardiovascular, inflammatory, liver, lung, metabolic and neurological disorders.

Hanmi Holdings Co. Ltd. has reported novel skeletal derivatives acting as HER2 mutant inhibitors and thus reported to be useful or the treatment of cancer.